Copyright
©The Author(s) 2015.
World J Gastroenterol. Aug 21, 2015; 21(31): 9337-9347
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9337
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9337
Table 1 Relationship between clinicopathological parameters and miR-30b expression
| Clinicopathologic parameter | Number of cases | 2-△△CT(mean) | P value |
| Age (yr) | 0.621 | ||
| ≥ 60 | 8 | 0.2078 ± 0.0285 | |
| < 60 | 15 | 0.2165 ± 0.0143 | |
| Gender | 0.427 | ||
| Male | 16 | 0.1951 ± 0.0198 | |
| Female | 7 | 0.2083 ± 0.0239 | |
| Lauren type | 0.371 | ||
| Intestinal type | 11 | 0.2148 ± 0.0316 | |
| Diffuse type | 12 | 0.1932 ± 0.0257 | |
| Lymph node metastasis | 0.021 | ||
| No | 9 | 0.2693 ± 0.0381 | |
| Yes | 14 | 0.1651 ± 0.0259 |
- Citation: Tian SB, Yu JC, Liu YQ, Kang WM, Ma ZQ, Ye X, Yan C. MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer. World J Gastroenterol 2015; 21(31): 9337-9347
- URL: https://www.wjgnet.com/1007-9327/full/v21/i31/9337.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i31.9337